✓ 1Q 2024 marks 15th consecutive quarter of >15% YOY royalty growth • Ocrelizumab SC (EU), mid-2024 ≫ | --- | --- | --- | |--------------------------|--------------|------------| | 1Q 2024 Phesgo ® Sales | Sales (CHFm) | Growth CER | | TOTAL | 338 | 70% | | US | 126 | 36% | | EU | 169 | 55% | | Japan | 19 | NA | | International | 74 | 165% | 8 2 Product Approvals Total DARZALEX® Sales IV+SC ($B) 1 85% of patients preferred Phesgo® for subcutaneous administration over the intravenous formulation of Perjeta a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 _______________________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ...

Exhibit 99.1 HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.791 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance: Total Revenue of $915 - $985 million, Representing YOY Growth of 10% - 19%, Adjusted EBITDA of $535 - $585 million, Representing YOY Growth of 26% - 37% and Non-GAAP Diluted EPS of ...

SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing busi ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Z ...

Halozyme Therapeutics (HALO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sco ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Conference Call February 20, 2024 4:30 PM ET Company Participants Tram Bui - VP, IR and Corporate Communications Helen Torley - President and CEO Nicole LaBrosse - CFO Conference Call Participants Jessica Fye - JPMorgan Michael DiFiore - Evercore ISI Mohit Bansal - Wells Fargo Mitchell Kapoor - H.C. Wainwright Jason Butler - JMP Securities Joe Catanzaro - Piper Sandler Jason Zhuang - Leerink Partners Corinne Johnson - Goldman Sachs Operator Hello an ...

| --- | --- | --- | |----------------------------------------------------------|-------|-------| | | | | | Halozyme Therapeutics, Inc. | | | | Fourth Quarter and FY 2023 Financial & Operating Results | | | | | | | | NASDAQ: HALO | | | | February 20, 2024 | | | | | | | In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including ...